MK1026-003
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
COVID-19: We are currently offering vaccinations to current qualifying patients. CURRENT PATIENTS VACCINATION INFO.
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
Learn more about our Cancer Treatment Team by scrolling below, or visit our Meet the Team page.